This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Eroxon (MED3000) (topical GTN (glyceryl trinitrate)) for erectile dysfunction (ED)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Eroxon (MED3000) (topical GTN (glyceryl trinitrate)) for erectile dysfunction (ED)

MED3000 Clinical Programme

  • MED3000 is a topical gel applied directly to the head (glans) of the penis for the treatment of male erectile dysfunction ("ED")

  • MED3000 is a treatment applied directly to the head (glans) of the penis and massaged for 15 seconds.
    • ED sufferers or their partners can apply the gel directly to the man's penis as part of foreplay (1)
    • is fast-acting helping men get an erection within 10 minutes, and easy to use helping to restore spontaneity and intimacy in the relationship whilst offering an excellent safety profile
    • utilises DermaSys technolody (1)
      • Dermasysis a drug delivery technology platform that provides rapid and targeted local delivery of active pharmaceutical ingredients (API) at therapeutic levels to the required site of action
      • application of gel with API leads to a combination of solvents including volatile solvents
        • then volatile solvents evaporate, leaving the remaining solvent supersaturated with API
        • in turn, derives API through the tissue and then API penetrated the skin rapidly offering rapid penetration or sustained release
      • GTN promotes vasodilation through local absorption into penile vasculature, minimising systemic uptake
        • GTN is absorbed into the penile blood system and is converted to nitric oxide, which has the effect of relaxing muscles surrounding the corpus cavernosa and dilating the penile arteries
        • allows the corpus cavernosa to engorge with blood and following sexual stimulation, an erection occurs

Evidence of benefit

  • FM71 is a multi-centre, randomised, open-label, home use, parallel group, clinical investigation of topically-applied MED3000 gel compared to tadalafil 5mgfor the treatment of ED over a 24-week period (1,2)

In a study (4)

  • MED3000, a topical gel, was tested on 250 patients in a 12-week, multi-center, randomized, double-blind, parallel-group study (FM57) that included men with a clinical diagnosis of ED for >3 months
  • patients or their female partners administered MED3000
  • in a second multi-center, randomized, open-label, parallel-group study (FM71), MED3000 was compared with 5 mg oral tadalafil over 24 weeks in 96 men with ED
  • study results:
    • approximately 60% of patients using MED3000 achieved clinically meaningful improvements in IIEF-EF domain scores in each of the two studies
    • 60.1% and 44.9% achieved erections in <10 minutes in FM57 and FM71, respectively
    • overall, less than 2% of the men who usedMED3000 and 4% of those who took tadalafil reported adverse effects
      • events included headaches in 3% of the combined MED3000 group and 19.1% of the tadalafil group
      • about1% of men who used MED3000 reported penile burning sensation compared with none in the group taking tadalafil
    • study authors concluded:
      • "..data from these pivotal studies resulted in the approval of MED3000 in the United States. MED3000 met the minimal clinically important difference (MCID) for improving erectile function with a favorable safety profile. This novel topical agent may be useful for men with ED who are not candidates for a phosphodiesterase type 5 (PDE5) inhibitor, who cannot tolerate adverse events associated with these agents, or who have suboptimal responses to them.."

Reference:

  • Futura Medical Developments Ltd. https://www.futuramedical.com/what-we-do/med3000/med3000-overview/
  • Ralph D et al. MED3000, a clinically proven, fast-acting topical product for Erectile Dysfunction with the prospect of being the first globally available OTC treatment for ED.European Society for Sexual Medicine (poster presentation).
  • Rosen RC et al “Minimal clinically important differences in the erectile function domain in the International Index of Erectile Function Scale Eur Urol 2011;60(5):1010-6
  • Hellstrom WJG et al. PD52-07 - Efficacy and safety of MED3000, a novel topical therapy for the treatment of erectile dysfunction. Journal of Urology 2024; 211 (5S): e1074

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.